The 112 references in paper A. Smirnov V., А. Смирнов В. (2010) “ЛЕЧЕНИЕ ГЛОМЕРУЛОПАТИЙ ЦИКЛОСПОРИНОМ: ПРАВИЛЬНЫЙ ПОДХОД С НЕВЕРНЫМ ОБОСНОВАНИЕМ // GLOMERULOPATHY TREATMENT BY CYCLOSPORINE: THE RIGHT APPROACH WITH THE WRONG RATIONALE” / spz:neicon:nefr:y:2010:i:4:p:9-22

1
Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007; 72 (12): 1429-1447
(check this in PDF content)
2
Козловская ЛВ. Хронический гломерулонефрит: ар­ гументы в пользу применения циклоспорина. Клиническая нефрология 2010; 3: 56-61
(check this in PDF content)
3
Захарова ЕВ, Бирюкова ЛС. Роль циклоспорина в ле­ чении идиопатического гломерулонефрита и волчаночного нефрита. Нефрология и диализ 2010; 12(2): 126-141
(check this in PDF content)
4
Calne RY Rolles K, White DJ et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2 (8151):1033-1036
(check this in PDF content)
5
Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009; 13(3): 403-417
(check this in PDF content)
6
Liu J, Farmer JD Jr, Lane WS et al. Calcineurin is a common target of cyclophilin- cyclosporin A and FKBP- FK506 complexes. Cell 1991; 66(4): 807-815
(check this in PDF content)
7
Thomson AW. The spectrum of action of new immunosuppressive drugs. Clin Exp Immunol 1992; 89(2): 170­ 173
(check this in PDF content)
8
Bram RJ, Hung DT, Martin PK et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993; 13(8): 4760­ 4769
(check this in PDF content)
9
Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J. 1994; 8(6): 391-400
(check this in PDF content)
10
Clardy J. The chemistry of signal transduction. Proc Natl Acad Sci USA 1995; 92(1): 56-61
(check this in PDF content)
11
Braun W, Kallen J, Mikol V et al. Three-dimensional structure and actions of immunosuppressants and their immunophilins. FASEB J. 1995: 9(1): 63-72
(check this in PDF content)
12
Tajima K, Amakawa R, Ito T et al. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003; 108(3):321-328
(check this in PDF content)
13
Galat A, Bua J. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci 2010; 67(20): 3467-3488
(check this in PDF content)
14
Мейл Д. Иммунология /Д. Мейл, Дж. Бростофф, Д.Б. Рот, А. Ройтт/ Пер. с англ. М: Логосфера 2007. - 568 с
(check this in PDF content)
15
Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 2(7880): 556-560
(check this in PDF content)
16
Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int 2009; 76(5): 487-491
(check this in PDF content)
17
Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 1992; 3 (6): 1260-1269
(check this in PDF content)
18
Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med
(check this in PDF content)
19
6; 334 (14): 878-883 19. Cattran D, Neogi T, Sharma R et al. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003; 14 (2): 448-453
(check this in PDF content)
20
Carraro M, Caridi G, Bruschi M et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid- resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13 (7): 1946-1952
(check this in PDF content)
21
Мухин НА, Тареева ИЕ, Краснова ТН, Шилов ЕМ, Мирошниченко НГ. Лечение нефротической формы хрони­ ческого гломерулонефрита сандиммуном (циклоспорином А). Тер арх 1995; 67 (8): 13-15
(check this in PDF content)
22
Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56 (6): 2220-2226
(check this in PDF content)
23
Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59 (4):1484-1490
(check this in PDF content)
24
Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev2008; 16 (3): CD003233
(check this in PDF content)
25
Austin HA 3rd, Illei GG, Braun MJ. Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20 (4): 901-911
(check this in PDF content)
26
Goumenos DS, Katopodis KP, Passadakis P et al. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol 2007; 27 (3): 226-231
(check this in PDF content)
27
Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch- Sch^lein glomerulonephritis. Pediatr Nephrol 2003; 18 (11):1138-1142
(check this in PDF content)
28
Alexopoulos E, Papagianni A, Tsamelashvili M et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006; 21 (11): 3127-3132
(check this in PDF content)
29
Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 2010; 19 (2): 162-169
(check this in PDF content)
30
Kiyomasu T, Shibata M, Kurosu H et al. Cyclosporin A treatment for membranoproliferative glomerulonephritis type II. Nephron 2002; 91 (3):509-511
(check this in PDF content)
31
Shin JI, Park JM, Shin YH et al. Cyclosporin A therapy for severe Henoch- S ch ^le in nephritis with nephrotic syndrome. Pediatr Nephrol 2005; 20 (8):1093-1097
(check this in PDF content)
32
Plank C, Kalb V, Hinkes B et al. Cyclosporin A is superior to cyclophosphamide in children with steroid- resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fbr Pдdiatrische Nephrologie. Pediatr Nephrol 2008; 23 (9): 1483-1493
(check this in PDF content)
33
Heidet L, Bongers EM, Sich M et al. In vivo expression of putative LMX1B targets in nail- patella syndrome kidneys. Am J Pathol 2003; 163 (1): 145-155
(check this in PDF content)
34
Meyrier A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transplant 1992; 7 Suppl 1: 80-84
(check this in PDF content)
35
Schrijver G, Assmann KJ, Wetzels JF, Berden JH. Cyclosporin A reduces albuminuria in experimental anti-GBM nephritis independently from changes in GFR. Nephrol Dial Transplant 1995; 10 (7): 1149-1154
(check this in PDF content)
36
Zietse R, Wenting GJ, Kramer P et al. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci (Lond) 1992; 82 (6): 641-650
(check this in PDF content)
37
Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980; 86 (2): 688-693
(check this in PDF content)
38
Rossi M, Morita H, Sormunen R et al. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 2003; 22 (2): 236-245
(check this in PDF content)
39
Harvey SJ, Jarad G, Cunningham J et al. Disruption of glomerular basement membrane charge through podocyte- specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171 (1): 139-152
(check this in PDF content)
40
Bensman A, Niaudet P Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010; 25 (7): 1197­ 1199
(check this in PDF content)
41
Charbit M, Gubler MC, Dechaux M et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007; 22 (1): 57-63
(check this in PDF content)
42
Massella L, Muda AO, Legato A et al. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 2010; 25 (7): 1269-1275
(check this in PDF content)
43
Malina M, Cinek O, Janda J, Seeman T. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol 2009; 24 (10): 2051-2053
(check this in PDF content)
44
Ruf RG, Lichtenberger A, Karle SM et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15 (3): 722-732
(check this in PDF content)
45
Gellermann J, Stefanidis CJ, Mitsioni A, Querfeld U. Successful treatment of steroid- resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol 2010; 25 (7): 1285-1289
(check this in PDF content)
46
Faul C, Asanuma K, Yanagida-Asanuma E et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17 (9): 428-437
(check this in PDF content)
47
Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010; 77 (7): 571-580
(check this in PDF content)
48
Kriz W, Hackenthal E, Nobiling R et al. A role for podocytes to counteract capillary wall distension. Kidney Int 1994; 45 (2): 369-376
(check this in PDF content)
49
St John PL, Abrahamson DR. Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. Kidney Int 2001; 60 (3): 1037-1046
(check this in PDF content)
50
Ina K, Kitamura H, Tatsukawa S et al. Clomerular podocyte endocytosis of the diabetic rat. J Electron Microsc (Tokyo) 2002; 51 (4): 275-279
(check this in PDF content)
51
Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001; 10 (4): 543-549
(check this in PDF content)
52
Kestila M, Lenkkeri U, Mдnnikkц M et al. Positionally cloned gene for a novel glomerular protein-nephrinis mutated in congenital nephrotic syndrome. Mol Cell 1998; 1 (4): 575-582
(check this in PDF content)
53
Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14 (9): 931-938
(check this in PDF content)
54
Miao J, Fan Q, Cui Q et al. Newly identified cytoskeletal components are associated with dynamic changes of podocyte foot processes. Nephrol Dial Transplant 2009; 24 (11): 3297­ 3305
(check this in PDF content)
55
Yoshikawa N, Ito H, Akamatsu R et al. Clomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch Pathol Lab Med 1986; 110 (5): 394-398
(check this in PDF content)
56
Farquhar MG, Palade GE. Clomerular permeability. II. Ferritin transfer across the glomerular capillary wall in nephrotic rats. J Exp Med 1961; 114: 699-716
(check this in PDF content)
57
Craham RC Jr, Karnovsky MJ. Clomerular permeability. Ultrastructural cytochemical studies using peroxidases as protein tracers. J Exp Med 1966; 124 (6): 1123-1134
(check this in PDF content)
58
Berg JG, van den Bergh Weerman MA, Assmann KJ et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66 (5): 1901-1906
(check this in PDF content)
59
Chuang PY He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009; 111 (2): p9-15
(check this in PDF content)
60
Ina K, Kitamura H, Tatsukawa S et al. Clomerular podocyte endocytosis of the diabetic rat. J Electron Microsc (Tokyo) 2002; 51 (4): 275-279
(check this in PDF content)
61
Hartleben B, Godel M, Meyer-Schwesinger C. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010; 120 (4): 1084-1096
(check this in PDF content)
62
Morigi M, Buelli S, Angioletti S et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005; 166 (5):1309-1320
(check this in PDF content)
63
Смирнов АВ, Добронравов ВА, Неворотин АИ и др. Гомоцистеин вызывает повреждения не только клубочково­ го, но и канальцевого отдела нефрона. Нефрология 2005; 9 (3) : 81-87
(check this in PDF content)
64
Смирнов АВ, Добронравов ВА, Неворотин АИ и др. Гипергомоцистеинемия усугубляет повреждения нефрона при экспериментальной хронической почечной недостаточ­ ности. Нефрология 2005; 9 (4): 67-74
(check this in PDF content)
65
Tipping PG. Are podocytes passive or provocative in proteinuric glomerular pathology? J Am Soc Nephrol 2008; 19 (4) : 651-653
(check this in PDF content)
66
Abe K, Miyazaki M, Koji T et al. Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization. Kidney Int 2001; 60 (1): 137-146
(check this in PDF content)
67
Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16 (5): 1195-1204
(check this in PDF content)
68
Couser WG, Nangaku M. Cellular and molecular biology of membranous nephropathy. J Nephrol 2006; 19 (6): 699-705
(check this in PDF content)
69
Topham PS, Haydar SA, Kuphal R et al. Complement- mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 1999; 55 (5) : 1763-1775
(check this in PDF content)
70
Yuan H, Takeuchi E, Taylor GA et al. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002; 13 (4): 946­ 956
(check this in PDF content)
71
Saran AM, Yuan H, Takeuchi E et al. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003; 64 (6): 2072-2078
(check this in PDF content)
72
Doublier S, Ruotsalainen V, Salvidio G et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158 (5): 1723-1731
(check this in PDF content)
73
Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361 (1): 11-21
(check this in PDF content)
74
Glassock RJ Human idiopathic membranous nephropathy-a mystery solved? N Engl J Med 2009; 361 (1): 81-83
(check this in PDF content)
75
Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 2010; 21 (4): 564-569
(check this in PDF content)
76
Lai KN, Leung JC, Chan LY et al. Podocyte injury induced by mesangial- derived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009; 24 (1): 62-72
(check this in PDF content)
77
Li X Kang YS, Dai C et al. Epithelial -to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172 (2): 299-308
(check this in PDF content)
78
Reiser J, von Gersdorff G, Loos M et al. Induction of B7- 1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113 (10): 1390-1397
(check this in PDF content)
79
Banas MC, Banas B, Hudkins KL et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008; 19 (4): 704-713
(check this in PDF content)
80
DAgati VD. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts). Kidney Int 2008; 73 (4): 399-406
(check this in PDF content)
81
Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69(12): 2131-2147
(check this in PDF content)
82
Torbjornsdotter TB, Perrin NE, Jaremko GA, Berg UB. Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes. Pediatr Nephrol 2005; 20 (6): 750-758
(check this in PDF content)
83
White KE, Bilous RW, Marshall SM et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51 (10): 3083-3089
(check this in PDF content)
84
Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42 (11): 1341-1344
(check this in PDF content)
85
Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007; 27 (2): 195-207
(check this in PDF content)
86
Wiggins RC The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007; 71 (12): 1205-1214
(check this in PDF content)
87
Patrakka J, Truggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009; 5 (8): 463-468
(check this in PDF content)
88
Reiser J, Gupta V, Kistler AD. Toward the development of podocyte-specific drugs. Kidney Int 2010; 77 (8): 662-668
(check this in PDF content)
89
Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002; 57 (4): 189-195
(check this in PDF content)
90
Kim YH, Goyal M, Kurnit D et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60 (3): 957-968
(check this in PDF content)
91
Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin- induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16 (10): 2941-2952
(check this in PDF content)
92
Kretzler M. Role of podocytes in focal sclerosis: defining the point of no return. J Am Soc Nephrol 2005; 16 (10): 2830­ 2832
(check this in PDF content)
93
Fogo AB Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 2000; 75: S15-21
(check this in PDF content)
94
Lu TC, He JC, Klotman PE. Podocytes in HIV-associated nephropathy. Nephron Clin Pract 2007; 106 (2): c67-71
(check this in PDF content)
95
He JC, Husain M, Sunamoto M et al. Nef stimulates proliferation of glomerular podocytes through activation of Src- dependent Stat3 and MAPK1, 2 pathways. J Clin Invest 2004; 114 (5): 643-651
(check this in PDF content)
96
Korgaonkar SN, Feng X, Ross MD et al. HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008; 19 (5): 877-883
(check this in PDF content)
97
Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2 (3): 529-542
(check this in PDF content)
98
Mathieson PW. Proteinuria and immunity - an overstated relationship? N Engl J Med 2008; 359 (23): 2492-2494
(check this in PDF content)
99
Mathieson PW. Podocyte actin in health, disease and treatment. Nephrol Dial Transplant 2010; 25 (6): 1772-1773
(check this in PDF content)
100
Yanagida-Asanuma E, Asanuma K, Kim K et al. Synaptopodin protects against proteinuria by disrupting Cdc42: IRSp53: Mena signaling complexes in kidney podocytes. Am J Pathol 2007; 171 (2): 415-427
(check this in PDF content)
101
Asanuma K, Kim K, Oh J et al. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform- specific manner. J Clin Invest 2005; 115 (5): 1188-1198
(check this in PDF content)
102
Asanuma K, Yanagida-Asanuma E, Faul C et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 2006; 8 (5): 485­ 491
(check this in PDF content)
103
Yan K, Kudo A, Hirano H et al. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int 1999; 56 (1): 65-73
(check this in PDF content)
104
Xing CY Saleem MA, Coward RJ et al. Direct effects of dexamethasone on human podocytes. Kidney Int 2006; 70 (6): 1038-1045
(check this in PDF content)
105
Castellino F, Heuser J, Marchetti S et al. Glucocorticoid stabilization of actin filaments: a possible mechanism for inhibition of corticotropin release. Proc Natl Acad Sci USA 1992; 89 (9): 3775-3779
(check this in PDF content)
106
Koukouritaki SB, Lianos EA. Glucocorticoid effect on human mesangial cell cytoskeletal proteins. J Lab Clin Med 1999; 133 (4): 378-383
(check this in PDF content)
107
Ranson RF, Lam NG, Hallett MA et al. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005; 68 (6): 2473-2483
(check this in PDF content)
108
Wada T, Pippin JW, Marshall CB et al. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol 2005; 16 (9): 2615-2625
(check this in PDF content)
109
Wada T, Pippin JW, Nangaku M, Shankland SJ. Dexamethasone’s prosurvival benefits in podocytes reguire extracellular signal-regulated kinase phosphorylation. Nephron Exp Nephrol 2008; 109 (1): e8-19
(check this in PDF content)
110
Wagrowska-Danilewicz M, Danilewicz M. Synaptopodin immunoexpression in steroid-responsive and steroid- resistant minimal change disease and focal segmental glomerulosclerosis. Nefrologia 2007; 27 (6): 710-715
(check this in PDF content)
111
Ehrich JH, Geerlings C, Zivicnjak M et al. Steroid- resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 2007; 22 (8): 2183-2193
(check this in PDF content)
112
Jain KK. Challenges of drug discovery for personalized medicine. Curr Opin Mol Ther 2006; 8 (6): 487-492 Поступила в редакцию 14.09.2010 г. Принята в печать 17.11.2010 г.
(check this in PDF content)